Provided by Tiger Trade Technology Pte. Ltd.

Vera Therapeutics, Inc.

35.28
+1.564.63%
Pre-market: 35.500.2200+0.62%05:16 EDT
Volume:2.49M
Turnover:86.87M
Market Cap:2.53B
PE:-5.98
High:35.57
Open:34.05
Low:34.00
Close:33.72
52wk High:56.05
52wk Low:21.15
Shares:71.71M
Float Shares:62.80M
Volume Ratio:1.65
T/O Rate:3.96%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.8984
EPS(LYR):-4.6644
ROE:-91.75%
ROA:-46.76%
PB:6.20
PE(LYR):-7.56

Loading ...

Vera Therapeutics appoints Christopher Hite to board

Reuters
·
Mar 10

Vera Therapeutics Grants Inducement Stock Options and RSUs to Six New Hires

Reuters
·
Mar 07

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Mar 07

Vera Therapeutics appoints Hite to Board of Directors

TIPRANKS
·
Mar 05

Vera Therapeutics Appoints Christopher Hite to Board of Directors

GlobeNewswire
·
Mar 05

Vera Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Mar 02

Bank of America Securities Reaffirms Their Buy Rating on Vera Therapeutics (VERA)

TIPRANKS
·
Mar 02

Vera Therapeutics price target raised to $110 from $90 at H.C. Wainwright

TIPRANKS
·
Mar 02

Positive Phase 3 IgA Data and FDA Priority Review Could Be A Game Changer For Vera Therapeutics (VERA)

Simply Wall St.
·
Feb 28

Vera Therapeutics: Strong Atacicept Phase 3 Data and Favorable Regulatory, Commercial Setup Support Buy Rating

TIPRANKS
·
Feb 28

Wedbush Raises Price Target on Vera Therapeutics to $35 From $33, Keeps Neutral Rating

MT Newswires Live
·
Feb 27

Guggenheim Keeps Their Buy Rating on Vera Therapeutics (VERA)

TIPRANKS
·
Feb 27

Vera Therapeutics Q4 EPS $(1.39) Misses $(1.31) Estimate

Benzinga Earnings
·
Feb 27

Vera Therapeutics: Buy Rating Backed by Strong Atacicept Data, Robust Cash Runway, and Large IgAN Market Opportunity

TIPRANKS
·
Feb 27

Vera Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary

Reuters
·
Feb 27

Vera Therapeutics' 2025 net loss wider than expectations

Reuters
·
Feb 26

Vera reports FY 2025 net loss of USD 299.6 million, R&D spend USD 215.3 million up 70.6%

Reuters
·
Feb 26

BRIEF-Vera Therapeutics FY EPS USD -4.66 Vs. IBES Estimate USD -4.55

Reuters
·
Feb 26

Vera Therapeutics FY Operating Expenses USD 315.473 Million

THOMSON REUTERS
·
Feb 26

Vera Therapeutics FY EPS USD -4.66 VS. Ibes Estimate USD -4.55

THOMSON REUTERS
·
Feb 26